유럽의 정형외과용 생체재료 시장 : 시장 규모, 동향 및 분석(2024-2030년) : MedSuite

Orthopedic Biomaterials Market Size, Share and Trends Analysis | Europe | 2024-2030 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more

US $ 8,995 ￦ 12,315,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 9,995 ￦ 13,684,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,995 ￦ 15,053,000

PDF (Corporate License)

PDF 보고서를 동일 기업(해외)의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

2023년 유럽의 정형외과용 생체재료 시장 규모는 5억 5,400만 유로를 넘어섰습니다. 이 시장은 CAGR 2.1%로 성장해 2030년에는 6억 4,300만 유로 가까이에 달할 것으로 예측되고 있습니다.

주요 인구동태의 동향이 계속 유럽의 정형외과용 생체재료 시장을 견인하고 있습니다. 특필해야 할 요인은 특히 인구의 고령화에 수반해 척추의 변형성 관절증(OA)의 발생률이 상승하고 있기 때문에 척추 고정술의 건수가 증가하고 있습니다. 2008년에 시작된 베이비 붐 세대의 제1파의 정년퇴직에 의해 고령화가 진행되는 가운데, 관절염이나 추간판 변성증에 대처하는 치료에 대한 수요가 높아지고 있습니다. 이 때문에 뼈 이식 대체물에 대한 요구가 커지고 있습니다. 게다가 비만률이 증가함에 따라 변성질환의 유병률은 더욱 가속화되어 정형외과용 생체재료와 관련 처치 수요를 촉진하고 있습니다. 이러한 추세는 예측 기간 동안 시장 성장을 가속할 것으로 예상됩니다.

Fidia는 회사의 HA 관절 내 보충 치료 제품인 Hyalubrix(R)와 Hyalgan(R)의 긍정적인 성과에 힘입어 유럽 정형외과용 생체재료 시장에서 선두 자리를 유지하고 있습니다. Medtronic은 주로 INFUSE(TM) 제품에 의한 정형외과용 성장인자 시장에서의 우위에 따라 2위를 차지했습니다. Bioventus는 주로 단일 주사 치료제인 DUROLANE®의 유럽 전역에서 주요 유통업체으로 3위 시장 점유율을 확보했습니다.

본 보고서에서는 유럽의 정형외과용 생체재료 시장을 조사했으며, 시장 개요와 함께 부문별 동향, COVID-19의 영향 분석, 시장 성장 촉진요인 및 저해 요인, 경쟁 시장 점유율 분석 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

주요 요약

조사 방법

세계 소화기 내시경 장비 시장에 대한 COVID-19의 영향

• 소개
• 지역 프로파일
• 시장 부문별 분석
  • 워스트 케이스 시나리오
  • 베이스 케이스 시나리오
  • 베스트 케이스 시나리오

질병 개요

• 기본적인 해부학
• 질병의 치료와 진단
• 환자 인구통계

제품 평가

• 소개
• 제품 포트폴리오
• 규제상의 문제와 리콜
• 임상시험

유럽 정형외과용 생체 재료 시장 개요

• 소개
• 환율
• 시장 개요와 트렌드 분석
• 성장 촉진요인과 억제요인
• 경쟁 시장 점유율 분석
• 합병과 인수
• 기업 프로파일
  • Arthrex
  • Biocomposites
  • Bioventus
  • DePuy Synthes
  • Ferring Pharmaceuticals
  • Isto Biologics
  • Medtronic
  • MTF
  • NuVasive
  • Orthofix
  • Sanofi
  • Stryker
  • Terumo
  • Vericel
  • Zimmer Biomet
• SWOT 분석

국가별 프로파일

• 소개
• 독일
• 프랑스
• 영국
• 이탈리아
• 스페인
• 베네룩스
• 스칸디나비아
• 오스트리아
• 스위스
• 포르투갈

수기 건수

정형외과용 골이식 대체품 시장

정형외과용 성장인자 시장

정형외과용 세포 치료 시장

히알루론산 윤활액 보충요법 시장

정형외과용 연골 복구 시장

JHS

영문 목차

영문목차

In 2023, the European market for orthopedic biomaterials was valued at over €554 million. This market is projected to grow at a compound annual growth rate (CAGR) of 2.1%, reaching nearly €643 million by 2030. The full report on the European orthopedic biomaterials market includes bone graft substitutes (allografts, demineralized bone matrices (DBMs), and synthetic bone grafts), orthopedic growth factors, cell therapies (bone marrow aspirate concentrate and platelet-rich plasma), hyaluronic acid (HA) viscosupplementation (single-, two-, three-, and five-injection cycles), and orthopedic cartilage repair (osteochondral allografts, meniscal allografts, autologous chondrocyte implantation, and osteochondral autografts).

MARKET DATA HIGHLIGHTS:

• Unit sales, average selling prices, market value, and growth trends
• Forecasts until 2030 and historical data from 2020
• Market drivers and constraints for each segment
• Competitive analysis with market shares for each segment
• Mergers & acquisitions
• Procedure volumes
• Company profiles, product portfolios, and SWOT analysis for top competitors

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET TRENDS

Key demographic trends continue to drive the European orthopedic biomaterials market. A notable factor is the rising incidence of osteoarthritis (OA) in the spine, particularly as the population ages, leading to an increasing number of spinal fusion procedures. With the aging population, driven by the retirement of the first wave of baby boomers starting in 2008, there has been a growing demand for treatments addressing arthritis and degenerative disc disease. This has led to an increased need for bone graft substitutes. Additionally, the prevalence of degenerative diseases is further accelerated by rising obesity rates, driving demand for orthopedic biomaterials and associated procedures. These trends are expected to propel market growth during the forecast period.

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET SHARE INSIGHTS (2023)

Fidia maintained its leadership position in the European orthopedic biomaterials market, bolstered by the strong performance of its HA viscosupplementation products, Hyalubrix(R) and Hyalgan(R).

Medtronic ranked as the second-largest player, largely due to its dominance in the orthopedic growth factor market with its INFUSE(TM) product.

Bioventus secured the third-largest market share, primarily as the leading distributor of DUROLANE(R), a single-injection treatment, across Europe.

MARKET SEGMENTATION SUMMARY

• Bone Graft Substitutes Market: Includes allografts, demineralized bone matrices (DBMs), and synthetic bone graft substitutes.
• Orthopedic Growth Factor Market: Segmented into spine and tibial fracture treatments.
• Orthopedic Cell Therapy Market: Includes platelet-rich plasma and bone marrow concentration segments.
• Hyaluronic Acid Viscosupplementation Market: Covers single-injection, two-injection, three-injection, and five-injection products.
• Orthopedic Cartilage Repair Market: Includes osteochondral allografts, meniscal allografts, autologous chondrocyte implantation (ACI), and osteochondral autografts.

GLOBAL RESEARCH SCOPE SUMMARY

• Region: Europe (France, U.K., Italy, Spain, Benelux, Scandinavia, Austria, Switzerland, Portugal)
• Base Year: 2023
• Forecast: 2024-2030
• Historical Data: 2020-2022
• Quantitative Coverage: Market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative Coverage: COVID-19 impact, market growth trends, market constraints, competitive analysis, SWOT for top competitors, mergers & acquisitions, company profiles, product portfolios, FDA recalls, disruptive technologies, disease overviews.
• Data Sources: Primary interviews with industry leaders, government physician data, regulatory data, hospital private data, import/export data, iData Research's internal database.

TABLE OF CONTENT

TABLE of CONTENTS

List of Figures

List of Charts

executive summary

European Orthopedic Biomaterials Market Overview

Competitive Analysis

Emerging Markets and Technologies

Market Trends

Market Developments

Market Segmentation

Procedure Segmentation

Key Report Updates

Version History

research methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems and Perform Secondary Research
• Step 3: Preparation for Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast and Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review and Market Release
• Step 9: Customer Feedback and Market Monitoring

impact of covid-19 on THE European Orthopedic Biomaterials Market

• 2.1 Introduction
  • 2.1.1 Treatable Population
• 2.2 Country Profiles
• 2.3 Analysis By Market Segment
  • 2.3.1 Worst Case Scenario
  • 2.3.2 Base Case Scenario
  • 2.3.3 Best Case Scenario

Product Assessment

• 3.1 Introduction
• 3.2 Product Portfolios
  • 3.2.1 Bone Graft Substitutes
  • 3.2.2 Growth Factors
    • 3.2.2.1.1 NELL-1 Bone Biologics
    • 3.2.2.1.2 INFUSE(R) by Medtronic
    • 3.2.2.1.3 OsteoAMP(R) by Bioventus Surgical
    • 3.2.2.1.4 OP-1(TM) by Stryker/Olympus Biotech (Delisted)
    • 3.2.2.1.5 The Osteogrow Study
    • 3.2.2.1.6 AUGMENT(R) Bone Graft
    • 3.2.2.1.7 Amplex(R) Osteobiologic Bone Graft Substitute
    • 3.2.2.1.8 i-Factor(TM) Peptide Bone Matrix
  • 3.2.3 Cell Therapy
    • 3.2.3.1 Platelet-Rich Plasma
    • 3.2.3.2 Bone Marrow Aspirate Concentrate
  • 3.2.4 Hyaluronic Acid Viscosupplementation (HAV)
  • 3.2.5 Cartilage Repair
• 3.3 Regulatory Issues and Recalls
  • 3.3.1 Bone Graft Substitute Market FDA Recalls
  • 3.3.2 Growth Factor Market FDA Recalls
• 3.4 Clinical Trials
  • 3.4.1 Bone Graft Substitute Market Clinical Trials
  • 3.4.2 Growth Factor Market Clinical Trials
  • 3.4.3 Cell Therapy Market Clinical Trials
  • 3.4.4 Hyaluronic Acid Viscosupplementation Market
  • 3.4.5 Cartilage Repair Market Clinical Trials

European Orthopedic Biomaterials Market Overview

• 4.1 Introduction
• 4.2 Currency Exchange Rate
• 4.3 Market Overview & Trend Analysis
• 4.4 Drivers and Limiters
  • 4.4.1 Market Drivers
  • 4.4.2 Market Limiters
• 4.5 Competitive Market Share Analysis
• 4.6 Mergers and Acquisitions
• 4.7 Company Profiles
  • 4.7.1 Arthrex
  • 4.7.2 Biocomposites
  • 4.7.3 Bioventus
  • 4.7.4 DePuy Synthes
  • 4.7.5 Ferring Pharmaceuticals
  • 4.7.6 Isto Biologics
  • 4.7.7 Medtronic
  • 4.7.8 MTF
  • 4.7.9 NuVasive
  • 4.7.10 Orthofix
  • 4.7.11 Sanofi
  • 4.7.12 Stryker
  • 4.7.13 Terumo
  • 4.7.14 Vericel
  • 4.7.15 Zimmer Biomet
• 4.8 SWOT Analysis
  • 4.8.1 Arthrex
  • 4.8.2 Biocomposites
  • 4.8.3 Bioventus
  • 4.8.4 DePuy Synthes
  • 4.8.5 Ferring Pharmaceuticals
  • 4.8.6 Isto Biologics
  • 4.8.7 Medtronic
  • 4.8.8 MTF
  • 4.8.9 NuVasive
  • 4.8.10 Orthofix
  • 4.8.11 Sanofi
  • 4.8.12 Stryker
  • 4.8.13 Terumo
  • 4.8.14 Vericel
  • 4.8.15 Zimmer Biomet

Country Profiles

• 5.1 Introduction
  • 5.1.1 GDP Per Capita
  • 5.1.2 Price Index
• 5.2 Germany
• 5.3 France
• 5.4 United Kingdom
• 5.5 Italy
• 5.6 Spain
• 5.7 Benelux
• 5.8 Scandinavia
• 5.9 Austria
• 5.10 Switzerland
• 5.11 Portugal

Procedure Numbers

• 6.1 Introduction
• 6.2 Procedures
  • 6.2.1 Orthopedic Bone Grafting Procedures
    • 6.2.1.1 Orthopedic Bone Grafting Procedures by Material
    • 6.2.1.2 Orthopedic Bone Grafting Procedures by Indication
    • 6.2.1.2.1 Average Units Used per Procedure by Indication
    • 6.2.1.3 Allograft Procedures by Indication
    • 6.2.1.4 DBM Procedures by Indication
    • 6.2.1.5 Synthetic Procedures by Indication
    • 6.2.1.6 Orthopedic Bone Grafting Procedures by Care Setting
  • 6.2.2 Orthopedic Growth Factor Procedures
    • 6.2.2.1 Orthopedic Growth Factor Procedures by Indication
    • 6.2.2.2 Orthopedic Growth Factor Procedures by Care Setting
  • 6.2.3 Orthopedic Cell Therapy Procedures
    • 6.2.3.1 Orthopedic Cell Therapy Procedures by Material Type
    • 6.2.3.2 Platelet-Rich Plasma Procedures
    • 6.2.3.3 Bone Marrow Aspirate Concentrate Procedures
    • 6.2.3.1 Orthopedic Cell Therapy Procedures by Care Setting
  • 6.2.4 Hyaluronic Acid Viscosupplementation Procedures
    • 6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle
    • 6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Care Setting
  • 6.2.5 Orthopedic Cartilage Repair Procedures
    • 6.2.5.1 Orthopedic Cartilage Repair Procedures by Type
    • 6.2.5.2 Orthopedic Cartilage Repair Procedures by Care Setting

orthopedic Bone Graft Substitute Market

• 7.1 Introduction
• 7.2 Market Overview
• 7.3 Market Analysis and Forecast
  • 7.3.1 Total Bone Graft Substitute Market
  • 7.3.2 Allograft Bone Graft Substitute Market
  • 7.3.3 Demineralized Bone Matrix Bone Graft Substitute Market
  • 7.3.4 Synthetic Bone Graft Substitute Market
• 7.4 Unit Analysis
  • 7.4.1 Total Bone Graft Substitute Unit Analysis
  • 7.4.2 Allograft Bone Graft Substitute Unit Analysis
    • 7.4.2.1 Allograft Bone Graft Substitute Units Sold by Indication
    • 7.4.2.1.1 Spine Allograft Bone Graft Substitute Units Sold by Anatomy
    • 7.4.2.1.2 Trauma Allograft Bone Graft Substitute Units Sold by Anatomy
    • 7.4.2.1.3 Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy
    • 7.4.2.1.4 Foot Reconstruction Allograft Bone Graft Substitute Units Sold
    • 7.4.2.1.5 Craniomaxillofacial Allograft Bone Graft Substitute Units Sold
    • 7.4.2.1.6 Oncology Allograft Bone Graft Substitute Units Sold
  • 7.4.3 Demineralized Bone Matrix Allograft Unit Analysis
    • 7.4.3.1 Demineralized Bone Matrix Allograft Units Sold by Indication
    • 7.4.3.1.1 Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy
    • 7.4.3.1.2 Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy
    • 7.4.3.1.3 Craniomaxillofacial Demineralized Bone Matrix Allograft Units Sold
  • 7.4.4 Synthetic Bone Graft Substitute Unit Analysis
    • 7.4.4.1 Synthetic Bone Graft Substitute Units Sold by Indication
    • 7.4.4.1.1 Spine Synthetic Bone Graft Substitute Units Sold by Anatomy
    • 7.4.4.1.2 Trauma Synthetic Bone Graft Substitute Units Sold by Anatomy
    • 7.4.4.1.3 Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy
    • 7.4.4.1.4 Foot Reconstruction Synthetic Bone Graft Substitute Units Sold
    • 7.4.4.1.5 Craniomaxillofacial Synthetic Bone Graft Substitute Units Sold
    • 7.4.4.1.6 Oncology Synthetic Bone Graft Substitute Units Sold
    • 7.4.4.2 Synthetic Bone Graft Substitute Market by Generation Type
    • 7.4.4.2.1 Generation 1 Synthetic Bone Graft Substitute Market
    • 7.4.4.2.2 Generation 2 Synthetic Bone Graft Substitute Market
• 7.5 Drivers and Limiters
  • 7.5.1 Market Drivers
  • 7.5.2 Market Limiters
• 7.6 Competitive Market Share Analysis

ORthopedic Growth Factor Market

• 8.1 Introduction
  • 8.1.1 BMP-2 (Medtronic)
• 8.2 Market Overview
• 8.3 Market Analysis and Forecast
  • 8.3.1 Orthopedic Growth Factor Market
  • 8.3.2 Spine Fracture Orthopedic Growth Factor Market
  • 8.3.3 Tibial Fracture Orthopedic Growth Factor Market
• 8.4 Unit Analysis
  • 8.4.1 Spine Orthopedic Growth Factor Unit Analysis
  • 8.4.2 Tibial Fracture Orthopedic Growth Factor Unit Analysis
• 8.5 Drivers and Limiters
  • 8.5.1 Market Drivers
  • 8.5.2 Market Limiters
• 8.6 Competitive Market Share Analysis

Orthopedic Cell Therapy Market

• 9.1 Introduction
• 9.2 Market Overview
• 9.3 Market Analysis and Forecast
  • 9.3.1 Platelet-Rich Plasma Market
  • 9.3.2 Bone Marrow Aspirate Concentrate Market
• 9.4 Unit Analysis
  • 9.4.1 Platelet-Rich Plasma Units Sold by Indication
    • 9.4.1.1 Soft-Tissue Platelet-Rich Plasma Units Sold
    • 9.4.1.2 Spine Platelet-Rich Plasma Units Sold
    • 9.4.1.3 Cardiac Platelet-Rich Plasma Units Sold
    • 9.4.1.4 Orthopedic Platelet-Rich Plasma Units Sold
    • 9.4.1.5 Plastics Platelet-Rich Plasma Units Sold
  • 9.4.2 Bone Marrow Aspirate Concentrate Units Sold by Indication
    • 9.4.2.1 Spine Bone Marrow Aspirate Concentrate Units Sold
    • 9.4.2.2 Soft-Tissue Bone Marrow Aspirate Concentrate Units Sold
    • 9.4.2.3 Trauma Bone Marrow Aspirate Concentrate Units Sold
    • 9.4.2.4 Joint Reconstruction Bone Marrow Aspirate Concentrate Units Sold
• 9.5 Drivers and Limiters
  • 9.5.1 Market Drivers
  • 9.5.2 Market Limiters
• 9.6 Competitive Market Share Analysis

Hyaluronic Acid Viscosupplementation Market

• 10.1 Introduction
  • 10.1.1 Benefits of Viscosupplementation
  • 10.1.2 Synovial Fluid
  • 10.1.3 Product Types
• 10.2 Market Overview
• 10.3 Market Analysis and Forecast
  • 10.3.1 Total Hyaluronic Acid Viscosupplementation Market
  • 10.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
  • 10.3.3 Two-Injection Hyaluronic Acid Viscosupplementation Market
  • 10.3.4 Three-Injection Hyaluronic Acid Viscosupplementation Market
  • 10.3.5 Five-Injection Hyaluronic Acid Viscosupplementation Market
• 10.4 Drivers and Limiters
  • 10.4.1 Market Drivers
  • 10.4.2 Market Limiters
• 10.5 Competitive Market Share Analysis

Orthopedic Cartilage Repair Market

• 11.1 Introduction
  • 11.1.1 Anatomy
  • 11.1.2 Methods for Cartilage Repair
    • 11.1.2.1 Osteochondral Allograft Transfer
    • 11.1.2.2 Autologous Chondrocyte Implantation (ACI)
    • 11.1.2.3 Meniscal Allograft Transplantation
    • 11.1.2.4 Osteochondral Autograft
• 11.2 Market Overview
• 11.3 Market Analysis and Forecast
  • 11.3.1 Osteochondral Allograft Market
  • 11.3.2 Meniscal Allograft Market
  • 11.3.3 Autologous Chondrocyte Implantation Market
  • 11.3.4 Osteochondral Autograft Market
• 11.4 Drivers and Limiters
  • 11.4.1 Market Drivers
  • 11.4.2 Market Limiters
• 11.5 Competitive Market Share Analysis

Abbreviations

관련자료